Docoh
Loading...

MOR Morphosys

APP
Utility
Anti-gm-csf Antibodies
11 Nov 21
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions.
Stefan STEIDL, Elisabeth THOMASSEN-WOLF
Filed: 7 May 21
APP
Utility
Canine Antibody Libraries
14 Oct 21
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
Filed: 22 Apr 21
APP
Utility
Treatment Paradigm for an ANTI-CD19 Antibody and Venetoclax Combination Treatment
23 Sep 21
The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
Peter Kelemen, Michael Schwarz, Mark Winderlich, Steffen Heeger, Dominika Weinelt
Filed: 30 May 18
APP
Utility
GENERATION AND PROFILING OF FULLY HUMAN HuCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38
23 Sep 21
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions.
Michael TESAR, Ute JÄGER
Filed: 9 Jun 21
APP
Utility
High Concentration Liquid Antibody Formulations
19 Aug 21
The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody.
Martin DOMNOWSKI, Roy EYLENSTEIN, Jan JAEHRLING, Daniel WEINFURTNER
Filed: 2 Jul 19
GRANT
Utility
Polypeptide library
10 Aug 21
The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement.
Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
Filed: 8 Apr 20
APP
Utility
Antibodies Targeting Glycoprotein VI
15 Jul 21
The present disclosure provides antibodies or antibody fragments specific for GPVI.
Kerstin UHLAND, Julia NEUGEBAUER, Steffen RUNZ
Filed: 15 May 19
GRANT
Utility
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
13 Jul 21
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions.
Michael Tesar, Ute Jäger
Filed: 7 Sep 18
GRANT
Utility
Nucleic acid encoding anti-GM-CSF antibodies
8 Jun 21
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions.
Stefan Steidl, Elisabeth Thomassen-Wolf
Filed: 17 Jun 19
GRANT
Utility
Canine antibody libraries
25 May 21
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
Filed: 21 Jun 18
APP
Utility
Treatment for Rheumatoid Arthritis
6 May 21
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis.
Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
Filed: 8 Jan 21
APP
Utility
ANTI-CD19 Therapy In Combination with Lenalidomide for the Treatment of Leukemia or Lymphoma
6 May 21
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients.
Sumeet Ambarkhane, Johannes Weirather
Filed: 30 Oct 20
APP
Utility
Anti-tumor Combination Therapy Comprising ANTI-CD19 Antibody and Gamma Delta T-cells
6 May 21
The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.
Jan Endell, Rainer Boxhammer, Dominik Pretscher
Filed: 30 Oct 20
GRANT
Utility
Rodent combinatorial antibody libraries
16 Feb 21
The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Josef Prassler, David Ott, Stefanie Thiel, Yvonne Stark, Ute Keck, Thomas Pietzonka, Hilmar Ebersbach
Filed: 10 Mar 17
GRANT
Utility
Treatment for rheumatoid arthritis
9 Feb 21
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis.
Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
Filed: 26 Jan 18
APP
Utility
ANTI-WT1/HLA-SPECIFIC Antibodies
28 Jan 21
The present invention relates to antibodies or fragments thereof binding to human WT1/HLA.
Andrea MAHR, Toni WEINSCHENK, Dominik MAURER, Claudia WAGNER, Klaus Felix HARTLEPP, Alexandra KRAUS
Filed: 13 Oct 20
APP
Utility
Peptide Libraries
23 Dec 20
The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
Katja Siegers, Jan Van Den Brulle
Filed: 7 Sep 20
APP
Utility
Humanized Antibodies for CD3
2 Dec 20
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells.
Thomas TILLER, Steffen RUNZ, Julia NEUGEBAUER, Andreas BÜLTMANN
Filed: 12 Aug 18
GRANT
Utility
Anti-WT1/HLA-specific antibodies
16 Nov 20
The present invention relates to antibodies or fragments thereof binding to human WT1/HLA.
Andrea Mahr, Toni Weinschenk, Dominik Maurer, Claudia Wagner, Klaus Felix Hartlepp, Alexandra Kraus
Filed: 6 Oct 16
APP
Utility
Combinations and Uses Thereof
11 Nov 20
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
Filed: 2 Apr 20
Patents are sorted by USPTO publication date, most recent first